X4 Pharmaceuticals (XFOR) Net Cash Flow (2017 - 2025)

X4 Pharmaceuticals' Net Cash Flow history runs 9 years deep, the most recent figure standing at $147.4 million for Q4 2025.

• Quarterly Net Cash Flow rose 455.4% year-over-year to $147.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $161.2 million (up 308.65% YoY) and the FY2025 annual result came in at $161.2 million, up 469.5% from the prior year.
• Net Cash Flow was $147.4 million for Q4 2025 at X4 Pharmaceuticals, up from $30.4 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $147.4 million in Q4 2025 and bottomed at -$52.8 million in Q3 2023.
• A 5-year average of $1.5 million and a median of -$15.4 million in 2022 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2022 — Net Cash Flow soared 654.31% — and 2023, when it tumbled 261.51%.
• X4 Pharmaceuticals' Net Cash Flow stood at $5.5 million in 2021, then surged by 654.31% to $41.5 million in 2022, then plunged by 178.24% to -$32.5 million in 2023, then retreated by 27.7% to -$41.5 million in 2024, then jumped by 455.4% to $147.4 million in 2025.
• Business Quant data shows XFOR's Net Cash Flow at $147.4 million in Q4 2025, $30.4 million in Q3 2025, and -$1.2 million in Q2 2025.